{
    "clinical_study": {
        "@rank": "8096", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "MM-141 monotherapy"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "MM-141 and Everolimus"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Experimental", 
                "description": "MM-141 and Abraxane and Gemcitabine"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a \"3+3\"\n      design, evaluating MM-141 at varying dose levels and frequencies."
        }, 
        "brief_title": "A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced malignant solid tumors for which no curative therapy exists that has\n             recurred or pgrogressed following standard therapy\n\n          -  Eighteen years of age or above\n\n          -  Able to understand and sign an informed consent (or have a legal representative who\n             is able to do so)\n\n          -  Measurable disease according to RECIST v1.1\n\n          -  ECOG Performance Score of 0 or 1\n\n          -  Adequate bone marrow, hepatic, renal and cardiac function\n\n          -  Willing to abstain from sexual intercourse or to use an effective form of\n             contraception during the study and for 90 days following the last dose of MM-141\n\n        Exclusion Criteria:\n\n          -  Active infection or fever > 38.5\u00b0C during screening visits or on the first scheduled\n             day of dosing\n\n          -  Symptomatic CNS disease\n\n          -  Received other recent antitumor therapy\n\n          -  Pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733004", 
            "org_study_id": "MM-141-01-01-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A", 
                "Arm B", 
                "Arm C"
            ], 
            "intervention_name": "MM-141", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cancer", 
            "Solid tumors", 
            "Oncology", 
            "Phase I", 
            "ErbB3", 
            "IGF-1R", 
            "Everolimus", 
            "Gemcitabine", 
            "Abraxane"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "christopher.moore@gacancer.com", 
                    "last_name": "Christopher Moore, RHIT, CTR", 
                    "phone": "770-496-9427"
                }, 
                "facility": {
                    "address": {
                        "city": "Marietta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Georgia Cancer Specialists"
                }, 
                "investigator": {
                    "last_name": "Mansoor Saleh, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Steven Isakoff, MD, PhD", 
                    "phone": "617-726-2000"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Steven Isakoff, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "formank@karmanos.org", 
                    "last_name": "Karen Forman, BAA, CCRP", 
                    "phone": "313-576-8096"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patricia LoRusso, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "monica.arnedos@igr.fr", 
                    "last_name": "Monica Arnedos, MD", 
                    "phone": "0033 1 42 11 40 68"
                }, 
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France"
                    }, 
                    "name": "Institut Goustave Roussy"
                }, 
                "investigator": {
                    "last_name": "Jean-Charles Soria, Pr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Akos Czibere, MD, PhD", 
            "phone": "617-441-1000"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the Phase II dose based either on the maximum tolerated dose (MTD) or recommended dose in patients with advanced solid malignancies.", 
            "measure": "Severity and number of adverse events related to escalating doses of MM-141", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merrimack Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merrimack Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}